Egyptian Ministry of Health decided to withdraw six medical preparations from the market after monitoring the adverse effects on the heart and nerves may lead to death.
Where Dr. Ashraf Bayoumi, Chairman of the Central Sector of Pharmaceutical Affairs, had been withdrawn six products registered containing the article "Bovlomidel" in all concentrations and forms of the pharmacy from the local market and Tharizha stores based on a decision of the Technical Committee to monitor the drugs issued by the Listing in 05/31/2011.
These include lotions, CD Ovil 150 mg, 300 mg and Pavlodel, and Villatol 300 mg and 150 mg, and Pavlomid 300 mg, 150 mg Vasumikan.
The Committee on pharmaceuticals Human Agency Alouribp Medicines Evaluation has issued a report on 20.05.2011 recommended the suspension of the use of preparations containing the article "Bovlomidel" until the completion of the evaluation currently under way to balance risk in relation to benefits for this article it was noted that the balance of Risks started to excel on the balance of benefits, and also by France to prevent the product already in February 2011 after monitoring the adverse effects on the heart and nerves may lead to death.
Where Dr. Ashraf Bayoumi, Chairman of the Central Sector of Pharmaceutical Affairs, had been withdrawn six products registered containing the article "Bovlomidel" in all concentrations and forms of the pharmacy from the local market and Tharizha stores based on a decision of the Technical Committee to monitor the drugs issued by the Listing in 05/31/2011.
These include lotions, CD Ovil 150 mg, 300 mg and Pavlodel, and Villatol 300 mg and 150 mg, and Pavlomid 300 mg, 150 mg Vasumikan.
The Committee on pharmaceuticals Human Agency Alouribp Medicines Evaluation has issued a report on 20.05.2011 recommended the suspension of the use of preparations containing the article "Bovlomidel" until the completion of the evaluation currently under way to balance risk in relation to benefits for this article it was noted that the balance of Risks started to excel on the balance of benefits, and also by France to prevent the product already in February 2011 after monitoring the adverse effects on the heart and nerves may lead to death.
